|
Apr 23
|
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
|
|
Apr 23
|
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
|
|
Apr 15
|
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable
|
|
Apr 15
|
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
|
|
Apr 12
|
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
|
|
Apr 11
|
Incyte to Report First Quarter Financial Results
|
|
Apr 6
|
Biotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury Says
|
|
Apr 1
|
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
|
|
Mar 31
|
12 Best S&P 500 Stocks To Buy According to Analysts
|
|
Mar 29
|
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 27
|
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
|
|
Mar 26
|
SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 14
|
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
|
|
Mar 12
|
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
|
|
Mar 11
|
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
|
|
Mar 10
|
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
|
|
Mar 10
|
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
|
|
Mar 7
|
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
|
|
Mar 4
|
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
|